Limits...
Intravitreal anti-vascular endothelial growth factor versus observation in acute central serous chorioretinopathy: one-year results.

Park SU, Lee SJ, Kim M - Korean J Ophthalmol (2014)

Bottom Line: Mean BCVA and CFT were not different between the two groups at 12 months (p > 0.05).The amount of change in BCVA, however, differed significantly between the groups (p = 0.044).In some patients, however, the rapid resolution of SRF by anti-VEGF might reduce the risk of photoreceptor degeneration and improve long-term visual acuity.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Kangwon National University School of Medicine, Chuncheon, Korea.

ABSTRACT

Purpose: To evaluate the efficacy of anti-vascular endothelial growth factor (VEGF) compared with observation for treating acute central serous chorioretinopathy (CSC).

Methods: A retrospective study of 36 patients with acute CSC, including 21 patients treated with anti-VEGF (anti-VEGF group) and 15 patients with observation (observation group). Patients in the anti-VEGF group received a single dose of bevacizumab or ranibizumab at baseline. Best-corrected visual acuity (BCVA), central foveal thickness (CFT) and resolution of subretinal fluid (SRF) on optical coherence tomography (OCT) were assessed. The integrity of the foveal inner segment/outer segment (IS/OS) line at 12 months was also analyzed.

Results: Resolution of SRF was achieved in 20 of 21 eyes in the anti-VEGF group and in 12 of 15 eyes in the observation group (p = 0.151). Mean BCVA and CFT were not different between the two groups at 12 months (p > 0.05). The amount of change in BCVA, however, differed significantly between the groups (p = 0.044). Final OCT more frequently detected the foveal IS/OS line in the anti-VEGF group than in the observation group (p = 0.012).

Conclusions: In terms of BCVA, anti-VEGF and observation only had similar therapeutic effects in acute CSC patients. In some patients, however, the rapid resolution of SRF by anti-VEGF might reduce the risk of photoreceptor degeneration and improve long-term visual acuity.

No MeSH data available.


Related in: MedlinePlus

Serial changes in the mean logarithm of the minimum angle of resolution (logMAR) for patients in the anti-vascular endothelial growth factor (VEGF) and the observation. Error bars represent the standard error of the mean. BCVA = best-corrected visual acuity.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4120351&req=5

Figure 1: Serial changes in the mean logarithm of the minimum angle of resolution (logMAR) for patients in the anti-vascular endothelial growth factor (VEGF) and the observation. Error bars represent the standard error of the mean. BCVA = best-corrected visual acuity.

Mentions: Mean BCVA changes from baseline in both groups are shown in Fig. 1. BCVA significantly improved from baseline over the entire follow-up period in both groups (p < 0.05). Comparison of the two groups revealed no statistically significant difference in BCVA improvement (p > 0.05) during the 12-month period, except at 1 month (p = 0.026). When the groups were stratified by the amount of change in BCVA (improved BCVA ≥0.1 logMAR, improved BCVA <0.1 logMAR, or loss BCVA <0.1 logMAR), however, significantly more patients in the anti-VEGF group (57.1%) had a moderate improvement in BCVA (<0.1 logMAR) than in the comparison group (26.7%), and none of the anti-VEGF group had a loss in BCVA, while 3 (20.0%) of the observation group patients had a loss in BCVA (Fig. 2).


Intravitreal anti-vascular endothelial growth factor versus observation in acute central serous chorioretinopathy: one-year results.

Park SU, Lee SJ, Kim M - Korean J Ophthalmol (2014)

Serial changes in the mean logarithm of the minimum angle of resolution (logMAR) for patients in the anti-vascular endothelial growth factor (VEGF) and the observation. Error bars represent the standard error of the mean. BCVA = best-corrected visual acuity.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4120351&req=5

Figure 1: Serial changes in the mean logarithm of the minimum angle of resolution (logMAR) for patients in the anti-vascular endothelial growth factor (VEGF) and the observation. Error bars represent the standard error of the mean. BCVA = best-corrected visual acuity.
Mentions: Mean BCVA changes from baseline in both groups are shown in Fig. 1. BCVA significantly improved from baseline over the entire follow-up period in both groups (p < 0.05). Comparison of the two groups revealed no statistically significant difference in BCVA improvement (p > 0.05) during the 12-month period, except at 1 month (p = 0.026). When the groups were stratified by the amount of change in BCVA (improved BCVA ≥0.1 logMAR, improved BCVA <0.1 logMAR, or loss BCVA <0.1 logMAR), however, significantly more patients in the anti-VEGF group (57.1%) had a moderate improvement in BCVA (<0.1 logMAR) than in the comparison group (26.7%), and none of the anti-VEGF group had a loss in BCVA, while 3 (20.0%) of the observation group patients had a loss in BCVA (Fig. 2).

Bottom Line: Mean BCVA and CFT were not different between the two groups at 12 months (p > 0.05).The amount of change in BCVA, however, differed significantly between the groups (p = 0.044).In some patients, however, the rapid resolution of SRF by anti-VEGF might reduce the risk of photoreceptor degeneration and improve long-term visual acuity.

View Article: PubMed Central - PubMed

Affiliation: Department of Ophthalmology, Kangwon National University School of Medicine, Chuncheon, Korea.

ABSTRACT

Purpose: To evaluate the efficacy of anti-vascular endothelial growth factor (VEGF) compared with observation for treating acute central serous chorioretinopathy (CSC).

Methods: A retrospective study of 36 patients with acute CSC, including 21 patients treated with anti-VEGF (anti-VEGF group) and 15 patients with observation (observation group). Patients in the anti-VEGF group received a single dose of bevacizumab or ranibizumab at baseline. Best-corrected visual acuity (BCVA), central foveal thickness (CFT) and resolution of subretinal fluid (SRF) on optical coherence tomography (OCT) were assessed. The integrity of the foveal inner segment/outer segment (IS/OS) line at 12 months was also analyzed.

Results: Resolution of SRF was achieved in 20 of 21 eyes in the anti-VEGF group and in 12 of 15 eyes in the observation group (p = 0.151). Mean BCVA and CFT were not different between the two groups at 12 months (p > 0.05). The amount of change in BCVA, however, differed significantly between the groups (p = 0.044). Final OCT more frequently detected the foveal IS/OS line in the anti-VEGF group than in the observation group (p = 0.012).

Conclusions: In terms of BCVA, anti-VEGF and observation only had similar therapeutic effects in acute CSC patients. In some patients, however, the rapid resolution of SRF by anti-VEGF might reduce the risk of photoreceptor degeneration and improve long-term visual acuity.

No MeSH data available.


Related in: MedlinePlus